pyrazines has been researched along with Hyperlipidemias in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (11.43) | 18.7374 |
| 1990's | 21 (60.00) | 18.2507 |
| 2000's | 3 (8.57) | 29.6817 |
| 2010's | 7 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Konishi, H; Kyohara, M; Okuyama, T; Shirakawa, J; Tajima, K; Terauchi, Y; Togashi, Y; Yamazaki, S | 1 |
| Chen, SL; Guo, CY; Liu, X; Miao, Y; Sun, MY; Wang, JS; Yin, HJ; Zhang, M; Zhang, SP | 1 |
| Huang, WJ; Li, JM; Liu, HC; Xie, D; Zhang, YC; Zuo, J | 1 |
| Guo, CY; Sun, MY; Wang, JS; Xu, FQ; Yin, HJ; Zhang, M | 1 |
| Akahane, D; Gotoh, M; Kitahara, T; Ohyashiki, K; Sakuta, J | 1 |
| Fontés, G; Hagman, DK; Latour, MG; Poitout, V; Semache, M | 1 |
| Bocchia, M; Chitarrelli, I; Defina, M; Fabbri, A; Gozzetti, A | 1 |
| Barnes, AA; Brown, AJ; Dowell, SJ; Eilert, M; Elshourbagy, N; Foord, SM; Fraser, NJ; Green, A; Hassall, DG; Ignar, DM; Marshall, FH; Murdock, PR; Pike, NB; Steplewski, K; Szekeres, PG; Wilson, S; Wise, A | 1 |
| Bajaj, M; Cline, GW; DeFronzo, RA; Mandarino, LJ; Romanelli, A; Shulman, GI; Suraamornkul, S | 1 |
| Cairoli, R; Fragiacomo, C; Noseda, G | 1 |
| Alberti, KG; Dyer, RG; Laker, MF; Stewart, MW | 1 |
| Agroyannis, B; Chondros, K; Exarchos, D; Kapetanaki, A; Konstadinidou, I; Koutsikos, D; Tsoutsos, D; Tzanatos, H | 1 |
| Knight, BL; O'Connor, B; O'Donnell, M; Perombelon, N; Reaveley, D; Seed, M | 1 |
| Barter, PJ; Liang, HQ; Rajaram, OV; Rye, KA | 1 |
| Braatvedt, G; Corrall, RJ; Newrick, PG; Stansbie, D | 1 |
| Scheen, AJ | 1 |
| Liang, J; Yu, Y; Zhang, X | 1 |
| Birkenhäger, JC; De Heide, L; Deckers, JW; Hoogerbrugge, N; Jansen, H; Zillikens, MC | 2 |
| Fogari, R; Lusardi, P; Marasi, G; Preti, P; Vanasia, A; Zoppi, A | 1 |
| Ho, LT; Hsiao, LC; Hwu, CM; Kwok, CF; Li, SH; Liu, YF; Shih, KC | 1 |
| Mir, MA; Oleesky, DA | 1 |
| Alberti, KG; Davoren, PM; Gries, FA; Hubinger, A; Kelly, W; Whately-Smith, C | 1 |
| Chan, DC; Chow, CC; Cockram, CS; Ko, GT; Lam, CW; Mak, TW; Tsang, LW; Yeung, VT | 1 |
| Algra, A; Banga, JD; de Bruint, TW; Erkelens, DW; Kanters, SD | 1 |
| Hamood, H; Morad, N; Naschitz, J; Yeshurun, D | 1 |
| Coates, P; Rees, A; Shuttleworth, D | 1 |
| Nicholls, DP; O'Kane, MJ; Trimble, ER; Trinick, TR; Tynan, MB | 1 |
| Noacco, C; Taboga, C; Tonutti, L | 1 |
| Davidoff, P; García de los Ríos, M; González, G; Ruiz, F; Silva, MA; Tapia, JC; Varas, MA | 1 |
| Barlow, CW; Jankelow, D; Myburgh, DP; Soicher, ER | 1 |
| Bremer, JM; Lintott, CJ; Scott, RS | 1 |
| Ball, MJ; Galton, D; Jones, DB; Mann, JI; Rechlass, JP; Stirling, C; Vella, M | 1 |
| de Castilho, LN; Quintão, EC | 1 |
1 review(s) available for pyrazines and Hyperlipidemias
| Article | Year |
|---|---|
Acipimox--a nicotinic acid analogue for hyperlipidaemia.
Topics: Humans; Hyperlipidemias; Hypolipidemic Agents; Pyrazines | 1991 |
15 trial(s) available for pyrazines and Hyperlipidemias
| Article | Year |
|---|---|
Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
Topics: Acyl Coenzyme A; Adiponectin; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucose Tolerance Test; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin; Male; Middle Aged; Muscle, Skeletal; Pyrazines | 2005 |
[Acipimox treatment of hyperlipidemia type II].
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Placebos; Pyrazines | 1982 |
The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidaemia.
Topics: Apolipoproteins B; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Middle Aged; Phospholipids; Placebos; Pyrazines; Simvastatin; Triglycerides | 1995 |
The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoprotein(a); Male; Middle Aged; Niacin; Pyrazines; Triglycerides | 1993 |
Suppression of lipolysis in normal man does not inhibit recovery from insulin-induced hypoglycaemia.
Topics: Acetoacetates; Adult; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Fatty Acids, Nonesterified; Female; Glycerol; Humans; Hyperlipidemias; Hypoglycemia; Hypolipidemic Agents; Insulin; Lipolysis; Male; Pyrazines | 1993 |
The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
Topics: Adult; Aged; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pyrazines; Simvastatin; Treatment Outcome; Triglycerides | 1997 |
Comparative study of acipimox and pravastatin in patients with combined hyperlipidemia.
Topics: Adolescent; Adult; Cross-Over Studies; Double-Blind Method; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Patient Compliance; Pravastatin; Pyrazines | 1997 |
Acipimox attenuates hypertriglyceridemia in dyslipidemic noninsulin dependent diabetes mellitus patients without perturbation of insulin sensitivity and glycemic control.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoproteins B; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Insulin; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pyrazines; Triglycerides | 1997 |
Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.
Topics: Apolipoprotein A-I; Apolipoproteins B; Blood Glucose; Cholesterol; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Fatty Acids, Nonesterified; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin; Male; Placebos; Pyrazines; Triglycerides | 1998 |
The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Pyrazines; Simvastatin; Treatment Outcome | 1998 |
Short-term efficacy and tolerability of combination therapy with lovastatin and acipimox in Chinese patients with type 2 diabetes mellitus and mixed dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; China; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pyrazines | 1998 |
Intensive lipid-lowering strategy in patients with diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diet; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Pyrazines; Simvastatin; Triglycerides | 1999 |
[Acipimox (Olbetam) as a secondary hypolipemic agent in combined hypertriglyceridemia and hyperlipidemia].
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Pyrazines; Triglycerides | 2000 |
A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia.
Topics: Adult; Aged; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niacin; Pyrazines | 1992 |
Acipimox in the treatment of patients with hyperlipidaemia: a double blind trial.
Topics: Adult; Double-Blind Method; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrazines; Random Allocation; Triglycerides | 1986 |
19 other study(ies) available for pyrazines and Hyperlipidemias
| Article | Year |
|---|---|
Metabolic recovery of lipodystrophy, liver steatosis, and pancreatic β cell proliferation after the withdrawal of OSI-906.
Topics: Animals; Cell Proliferation; Dietary Supplements; Energy Metabolism; Fatty Liver; Hyperglycemia; Hyperinsulinism; Hyperlipidemias; Imidazoles; Insulin-Secreting Cells; Leptin; Lipodystrophy; Mice; Pyrazines; Safety-Based Drug Withdrawals; Time Factors; Tomography, X-Ray Computed | 2017 |
The Influence of Hyperlipidemia on Endothelial Function of FPN1 Tek-Cre Mice and the Intervention Effect of Tetramethylpyrazine.
Topics: Animals; Antioxidants; Aorta; Cation Transport Proteins; Drugs, Chinese Herbal; Endothelial Cells; Female; Hepcidins; Hyperlipidemias; Iron Overload; Male; Mice, Inbred C57BL; Oxidative Stress; Pyrazines | 2018 |
[Synthesis and biological evaluation of novel chalcone aromatic oxygen alkyl acids compounds].
Topics: Adenosine Diphosphate; Animals; Arachidonic Acid; Chalcones; Hyperlipidemias; Hypolipidemic Agents; Mice, Inbred C57BL; Oxygen; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrazines | 2016 |
Effect of tetramethylpyrazine and hyperlipidemia on hepcidin homeostasis in mice.
Topics: Animals; Female; Hepcidins; Homeostasis; Hyperlipidemias; Lipid Metabolism; Lipids; Liver; Male; Mice, Inbred C57BL; Models, Biological; Phosphorylation; Pyrazines; STAT3 Transcription Factor | 2019 |
Multiple lipoma with hyperlipidemia in a multiple myeloma patient treated with bortezomib/dexamethazone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Humans; Hyperlipidemias; Lipoma; Male; Middle Aged; Multiple Myeloma; Neoplasms, Multiple Primary; Pyrazines | 2010 |
Lack of preservation of insulin gene expression by a glucagon-like peptide 1 agonist or a dipeptidyl peptidase 4 inhibitor in an in vivo model of glucolipotoxicity.
Topics: Analysis of Variance; Animals; Blood Glucose; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Eating; Exenatide; Fat Emulsions, Intravenous; Gene Expression; Glucagon-Like Peptide 1; Glucose; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Lipids; Male; Peptides; Pyrazines; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Hyperlipidemia in a myeloma patient after bortezomib treatment.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Hyperlipidemias; Multiple Myeloma; Pyrazines | 2010 |
Molecular identification of high and low affinity receptors for nicotinic acid.
Topics: Amino Acid Sequence; Animals; Cell Membrane; CHO Cells; Cricetinae; Databases as Topic; DNA, Complementary; Dose-Response Relationship, Drug; Female; Furans; Humans; Hyperlipidemias; Hypolipidemic Agents; Inhibitory Concentration 50; Male; Molecular Sequence Data; Niacin; Oocytes; Protein Binding; Pyrazines; Rats; Receptors, Nicotinic; RNA, Messenger; Sequence Homology, Amino Acid; Tissue Distribution; Xenopus | 2003 |
Lipid-lowering effect and safety of acipimox in hemodialysis patients and renal transplant recipients.
Topics: Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Transplantation; Lipids; Male; Middle Aged; Pyrazines; Renal Dialysis; Uremia | 1994 |
Relationship between the size and phospholipid content of low-density lipoproteins.
Topics: Apolipoproteins B; Cholesterol; Electrophoresis, Polyacrylamide Gel; Humans; Hyperlipidemias; Lipoproteins, LDL; Molecular Weight; Phospholipids; Pyrazines; Triglycerides | 1993 |
[Pharma clinics. Drug of the month. Acipimox (Olbetam)].
Topics: Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemias; Hypolipidemic Agents; Pyrazines | 1995 |
[Effect of olbetam on hyperlipidemia in NIDDM].
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrazines; Triglycerides | 1995 |
Paradoxical high-density lipoprotein reduction induced by fibrate therapy.
Topics: Adult; Bezafibrate; Cholesterol, HDL; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Pyrazines | 1997 |
Resolution of nicotinic acid-induced acanthosis nigricans by substitution of an analogue (acipimox) in a patient with type V hyperlipidaemia.
Topics: Acanthosis Nigricans; Adult; Axilla; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Nicotinic Acids; Pyrazines | 1992 |
[Comparison of the efficacy of pantethine, acipimox, and bezafibrate on plasma lipids and index of cardiovascular risk in diabetics with dyslipidemia].
Topics: Bezafibrate; Cardiovascular Diseases; Diabetes Complications; Humans; Hyperlipidemias; Hypolipidemic Agents; Pantetheine; Pyrazines; Risk Factors | 1991 |
[Acipimox in primary hyperlipidemias: safety and efficacy evaluated in six months].
Topics: Adolescent; Adult; Aged; Cholesterol; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrazines; Triglycerides | 1991 |
Safety, tolerability and efficacy of acipimox in type II hyperlipidaemia.
Topics: Cholesterol; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrazines | 1990 |
Treatment of hyperlipidaemia with acipimox.
Topics: Adult; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins; Male; Middle Aged; Pyrazines | 1989 |
[Treatment of primary hyperlipidemia with 5-methylpyrazinecarboxylic acid (acipimox)].
Topics: Adolescent; Adult; Aged; Cholesterol; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrazines; Triglycerides | 1985 |